Jeremy Bender Sells 70,051 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 70,051 shares of Day One Biopharmaceuticals stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $17.88, for a total value of $1,252,511.88. Following the completion of the transaction, the chief executive officer now owns 651,762 shares in the company, valued at $11,653,504.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Jeremy Bender also recently made the following trade(s):

• On Friday, May 3rd, Jeremy Bender sold 9,154 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $17.85, for a total value of $163,398.90.
• On Friday, February 16th, Jeremy Bender sold 7,615 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $15.25, for a total value of $116,128.75.

Day One Biopharmaceuticals Trading Down 2.3 %

NASDAQ DAWN opened at $17.17 on Friday. The company has a market capitalization of $1.50 billion, a PE ratio of -7.21 and a beta of -1.44. Day One Biopharmaceuticals, Inc. has a 1-year low of $9.67 and a 1-year high of $18.07. The firm’s fifty day simple moving average is $15.45 and its 200-day simple moving average is $14.02.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). As a group, analysts predict that Day One Biopharmaceuticals, Inc. will post -2.67 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on DAWN. Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, April 24th. Needham & Company LLC lifted their price objective on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. JPMorgan Chase & Co. lifted their price target on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Monday, April 22nd. Finally, Piper Sandler reissued an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.33.

Institutional Trading of Day One Biopharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its holdings in shares of Day One Biopharmaceuticals by 58.7% during the 3rd quarter. SG Americas Securities LLC now owns 36,980 shares of the company’s stock valued at $454,000 after purchasing an additional 13,683 shares in the last quarter. Bank of New York Mellon Corp increased its position in Day One Biopharmaceuticals by 22.4% during the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock worth $2,703,000 after buying an additional 40,387 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Day One Biopharmaceuticals by 24.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 43,567 shares of the company’s stock valued at $535,000 after buying an additional 8,522 shares in the last quarter. TD Asset Management Inc lifted its position in shares of Day One Biopharmaceuticals by 100.0% in the third quarter. TD Asset Management Inc now owns 55,196 shares of the company’s stock worth $677,000 after buying an additional 27,598 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in shares of Day One Biopharmaceuticals by 89.5% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 53,803 shares of the company’s stock worth $660,000 after acquiring an additional 25,414 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.